Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
|Articles|January 26, 2022
Daily Medication Pearl: Efgartigimod alfa-fcab (Vyvgart)
Author(s)Saro Arakelians, PharmD
Efgartigimod alfa-fcab (Vyvgart) is a human immunoglobulin G1 antibody fragment indicated for the treatment of generalized myasthenia gravis.
Advertisement
Medication Pearl of the Day: Efgartigimod alfa-fcab (Vyvgart)
Indication: Efgartigimod alfa-fcab (Vyvgart)is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive.
Insight:
- Dosing: The recommended dosage is 10 mg/kg administered as an intravenous infusion over 1 hour once weekly for 4 weeks.
- Dosage forms: Injection 400 mg in 20 mL (20 mg/mL) single-dose vial.
- Adverse events: Most common adverse reactions (≥ 10%) in patients treated with gMG are respiratory tract infections, headache, and urinary tract infection.
- Mechanism of action: Efgartigimod alfa-fcab is a human immunoglobulin G1 (IgG1) antibody fragment that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.
- Manufacturer: Argenx
Sources:
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
5